A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Fulvestrant (Primary) ; Letrozole (Primary) ; Palbociclib (Primary) ; Goserelin
- Indications Breast cancer
- Focus Adverse reactions
- 22 Jun 2017 Status changed from not yet recruiting to recruiting.
- 18 May 2017 Planned End Date changed from 30 Apr 2021 to 30 Jun 2021.
- 18 May 2017 Planned primary completion date changed from 31 May 2019 to 31 Jul 2019.